This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment has been made for the HTA database.
CADTH. Tiotropium compared with ipratropium for patients with moderate to severe chronic obstructive pulmonary disease: a review of the clinical effectiveness. Ottawa: Canadian Agency for Drugs and Technologies in Health (CADTH). 2012
Tiotropium appears to help improve objective lung function test measures, reduce the proportion of patients with =1 exacerbation, and improve COPD-related symptoms. There were conflicting results between the two included reports regarding a reduction in frequency of exacerbations. The use of tiotropium did not demonstrate a survival benefit.
Subject indexing assigned by CRD
Ipratropium; Pulmonary Disease, Chronic Obstructives; Scopolamine Derivatives
Country of organisation
An English language summary is available.
Address for correspondence
Canadian Agency for Drugs and Technologies in Health (CADTH), 865 Carling Avenue, Suite 600, K1S 5S8 Ottawa, Ontario Canada Email: firstname.lastname@example.org
Date abstract record published